Company: LBRX
Filing Date: 2025-07-23
Form Type: DRS/A
Source: 0000950123-25-006557
Chunk: 307

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-07-23
Form: DRS/A
Chunk 307
---
In August 2023, we issued warrants to Maxim Group LLC to purchase 1,528,632 shares of our common stock at an exercise price per share of $0.01,
subject to adjustment as set forth in the warrant, or the Maxim Warrants, which are currently held by Maxim Partners LLC. As of December 31, 2024, the Maxim Warrants remained unexercised. The Maxim Warrants include a cashless exercise feature
allowing the holder to receive shares underlying the Maxim Warrant in an amount reduced by the aggregate amount of the exercise price that would have been payable upon exercise of the Maxim Warrant for such shares. Each Maxim Warrant is exercisable
until its expiration in August 2033. The Maxim Warrants include anti-dilution protection provisions, subject to certain exceptions, relating to subsequent sales of shares of our common stock at an issuance price per share that is less than the
then-effective exercise price of the Maxim Warrants. The warrant holder has certain demand and piggyback registration rights.

New Series B Warrants

In August 2023, we issued warrants to certain investors to purchase 100,373 shares of our common stock at an exercise
price per share of $1.50, subject to adjustment as set forth in the warrant, or the New Series B Warrants. As of December 31, 2024, New Series B Warrants to purchase up to 98,456 shares of our common stock remained unexercised. The New Series B
Warrants include a cashless exercise feature allowing the holder to receive shares underlying the applicable New Series B Warrant in an amount reduced by the aggregate amount of the exercise price that would have been payable upon exercise of the
applicable New Series B Warrant for such shares. Each New Series B Warrant is exercisable until its expiration in August 2028. The New Series B Warrants include anti-dilution protection provisions, subject to certain exceptions, relating to
subsequent sales of shares of our common stock at an issuance price per share that is less than the then-effective exercise price of the New Series B Warrants. The warrant holder is not a stockholder and has none of the rights of a stockholder until
the warrant is exercised and the shares of common stock are issued upon exercise.

210

Investors’ Rights Agreement

In August 2023, in connection with the issuance and sale of our Series C preferred stock, we entered into an Investors’ Rights Agreement,
or